Skip to main content
OpenTrials
Completed

NCT Number: NCT04354909

Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Bordeaux

Bordeaux, France

About this study

Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) belongs to a TNF (tumor necrosis factors) receptor family. It knows to play a preponderant role to maintain the eye immune privilege. In particular conditions depending on immunologic environment, CD95-L has pro-inflammatory properties and can interact with Th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. The hypothesis is that s-CD95-L levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets.

This study will recruit 100 patients with non-infectious uveitis followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected during to assess s-CD95-L. Fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms.

Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, accordingly to usual care.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of non-infectious uveitis according to the SUN (Standardization of the Uveitis Nomenclature) working Group;
  • Age ≥ 18 years;
  • being affiliated to health insurance,
  • willing to participate.

Exclusion criteria

  • Pregnant or breastfeeding women,
  • patient under legal protection measure ,
  • poor understanding of the French language

Treatment and study plan

s-CD95-L

Other

levels of s-CD95-L (ELISA test)

Primary outcomes

  1. levels of s-CD95-L

    Time frame: Baseline

    levels of s-CD95-L (ELISA test) in sera of non-infectious uveitis patients

Secondary outcomes

  1. Correlation between levels of s-CD95-L and Disease activity score

    Time frame: Baseline, Month 3

    Correlation between levels of s-CD95-L and Disease activity score (as defined by ophthalmologic examination)

  2. Th17 dosage

    Time frame: Baseline, Month 3

    Th17 dosage

  3. polynuclear neutrophils levels

    Time frame: Baseline, Month 3

    polynuclear neutrophils levels (Flow cytometry)

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Acronym: UVE-FAS

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Apr 21, 2020
Registry last updated
May 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.